FDA tweaks and fi­nal­izes bioavail­abil­i­ty study guid­ance, but most­ly ig­nores Pfiz­er and Mer­ck sug­ges­tions

Ever since Rob Califf won Sen­ate con­fir­ma­tion as FDA com­mis­sion­er, the trick­le of new guid­ance doc­u­ments for the bio­phar­ma in­dus­try has be­come a steady stream …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER